-
Stifel: Atreca Offers Attractive Oncology Drug Development Play
Monday, July 15, 2019 - 2:22pm | 367Read More...The oncology drug development space holds “tremendous scarcity value for novel targets," and Atreca Inc’s (NASDAQ: BCEL) stock offers an investment opportunity at an attractive valuation, according to Stifel. The Analyst Stephen Willey initiated coverage of Atreca with a Buy...
-
Stifel Cuts NewLink Valuation Estimate In Half On Regulatory, Development Risks
Wednesday, August 1, 2018 - 3:31pm | 372Read More...Despite exceeding bottom-line expectations, NewLink Genetics Corp (NASDAQ: NLNK) plummeted Wednesday on second-quarter sales that were nearly 50 percent below projections. Stifel Nicolaus sees little visibility for NewLink going forward. The Rating Stifel Nicolaus analyst Stephen...
-
Stifel Doubles Down On MEI Pharma, Considers ME-401 'Best-In-Class'
Friday, July 27, 2018 - 10:29am | 410Read More...MEI Pharma Inc (NASDAQ: MEIP) is down 31.5 percent from its one-year high struck after the release of preliminary data for ME-401. Stifel Nicolaus considers the decline a stake-building opportunity. The Analyst Analyst Stephen Willey upgraded MEI from Hold to Buy and raised the...
-
Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking
Thursday, June 28, 2018 - 11:42am | 408Read More...The Food and Drug Administration approved Array Biopharma Inc (NASDAQ: ARRY)’s combination therapy of Mektovi and Braftovi in the treatment of BRAF-mutant melanoma on Wednesday. The stock, which rallied ahead of the news, subsequently plunged as investors walked with profits — but...
-
Stifel's ASCO Abstract Cheat Sheet
Thursday, May 18, 2017 - 9:57am | 587Read More...Commenting on the abstracts for the annual American Society of Clinical Oncology, or ASCO, meeting released after market close on Wednesday, Stifel gave its overview of the specific abstracts. The ASCO is scheduled to be held June 2–6 this year. Sell-Off In NewLink Genetics Unfounded...
-
Stifel Remains Buyers Of Ophthotech As Year-End Binary Event Looms
Friday, December 2, 2016 - 10:13am | 227Read More...Top-line data is expected from two of Ophthotech Corp (NASDAQ: OPHT)'s pivotal Phase III trials in the next month. Leading into the catalyst, which could take the stock either way, Stifel analyst Stephen Willey maintains a Buy rating and $75 price target on the stock, representing about 135 upside...
-
The Street's Confidence In Cempra Is Broken
Thursday, November 3, 2016 - 3:32pm | 298Read More...Cempra Inc (NASDAQ: CEMP) shares are now down a staggering 69 percent in the past month following new concerns by federal regulators about the safety of its experimental antibiotic solithromycin. The Federal Drug Administration is holding a public advisory panel this week and has acknowledged the...
-
BioMarin's Carnage Could Be Buying Opportunity, Says Stifel
Tuesday, February 16, 2016 - 12:06pm | 317Read More...According to a recent research summary from Stifel, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is deserving of an upgrade. Analysts Stephen Willey and Prakhar Verma began, “While acknowledging this isn't the easiest of environments for upgrading stocks, we do believe sector...
-
Downside Alert: Here's Exactly Why OncoGenex Pharma Is Having An Awful Start To December
Wednesday, December 2, 2015 - 12:41pm | 514Read More...Shares of OncoGenex Pharmaceuticals Inc (NASDAQ: OGXI) plunged more than 30 percent on Wednesday. OncoGenex said that its Phase 3 AFFINITY trial with custirsen is continuing following an interim analysis. Stephen Willey of Stifel downgraded shares of OncoGenex to Hold despite shares trading at/...
-
Tetraphase's Stock Just Lost 80%, You Should Flush It...Right?
Wednesday, September 9, 2015 - 2:22pm | 780Read More...Shares of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) plunged nearly 80 percent on Wednesday, trading as low as $9.00 per share. The massive selloff is attributed to the company failing to meet the primary endpoint of statistical non-inferiority for IGNITE2 compared to levofloxacin. Here is a...
-
Analyst Sees No Rival Bids For Auspex Pharmaceuticals
Tuesday, March 31, 2015 - 11:57am | 186Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) won't attract rivals for its $3.2 billion bid for Auspex Pharmaceuticals Inc (NASDAQ: ASPX), an analyst said Tuesday. Stifel's Stephen Willey downgraded Auspex to Hold and called its acquisition, at $101 a share, "a great strategic fit" for...
-
UPDATE: Stifel Reiterates Raises PT On Cempra On Good Risk/Reward Profile
Wednesday, December 31, 2014 - 8:31am | 135Read More...In a report published Wednesday, Stifel analyst Stephen Willey reiterated a Buy rating on Cempra Inc (NASDAQ: CEMP), and raised the price target from $22.00 to $33.00. In the report, Stifel noted, “Despite recent price appreciation, we continue to like risk/reward ahead of what we believe will be...
-
UPDATE: Stifel Reiterates On MacroGenics On Strategic Development Shift
Wednesday, November 12, 2014 - 11:05am | 124Read More...In a report published Wednesday, Stifel analyst Stephen Willey reiterated a Buy rating on MacroGenics (NASDAQ: MGNX), but lowered the price target from $53.00 to $51.00. In the report, Stifel noted, “The strategic shift in P3 margetuximab development shouldn't materially-impact commercialization...
-
UPDATE: Stifel Reiterates On Ophthotech Corp Following 3Q14 Report
Wednesday, November 12, 2014 - 10:55am | 72Read More...In a report published Wednesday, Stifel analyst Stephen Willey reiterated a Buy rating on Ophthotech Corp (NASDAQ: OPHT), and raised the price target from $58.00 to $59.00. In the report, Stifel noted, “P3 enrollment remains on track and the tivozantib licensing agreement creates some additional...
-
UPDATE: Stifel Reiterates On Tekmira Pharmaceuticals Ahead Of Analyst Day
Friday, November 7, 2014 - 10:33am | 87Read More...In a report published Friday, Stifel analyst Stephen Willey reiterated a Buy rating on Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), but lowered the price target from $31.00 to $26.00. In the report, Stifel noted, “We expect the November 21st analyst day to provide additional granularity...
